Compare AbbVie Inc (ABBV) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs JPMorgan Chase & Co — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while JPMorgan Chase & Co trades at $331.77 (market cap $908.94B). The key difference: JPMorgan Chase & Co is far larger — about 2× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | JPM | |
|---|---|---|
Market Cap | $449.91B | $908.94B |
Sector | Health | Financials |
52-Week High | $261.07 | $339.22 |
52-Week Low | $184.85 | $282.78 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 1.77% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
JPMorgan Chase (JPM) trades at $331.81, down 1.75% over the past day, with a bullish technical outlook and strong analyst consensus. The stock shows robust fundamentals, including a 31.61% net income margin and 17.03% ROE, supported by recent earnings beats. Revenue grew to $181.85B in 2025, though net income dipped slightly. Technical indicators signal bullish momentum, with moving averages supporting an uptrend and key resistance near $341.
The outlook for JPM remains positive, driven by solid profitability and Wall Street's moderate buy rating. Risks include geopolitical tensions and cybersecurity threats, but institutional buying and a $360.38 price target suggest upside potential. Investors should monitor Q2 2026 earnings for confirmation of growth trends amid volatile market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
